Modern proteomic biomarker discovery generally produces a panel of 5 - 50 candidates that require further qualification in a larger cohort of samples. In this context the biomarkers are usually tryptic peptides and replication studies often use antibodies against the parent protein. Selected Reaction Monitoring (SRM) is a multiplexed, targeted mass spectrometry assay format for the routine measurement of biomarkers that is particularly suited to monitoring candidates that do not have validated commercially available antibodies especially post-translational modifications. Our SRM assay development service produces bespoke assay panels with defined performance characteristics that are suitable for routine use in large study cohorts. Our expert team will guide you in the best workflow for your biomarker candidates, including selection of proteotypic peptides and optimization of sample preparation where appropriate.
The SRM Assay Development Process:
|Phase 1||Selection of proteotypic peptides|
|Phase 2||Ordering AQUA peptides (if required)|
|Phase 3||SRM assay development and validation|
|Phase 4||Optimization of sample preparation (if required)|
|Phase 5||Biomarker qualification in small cohort|
|Phase 6||Biomarker validation in larger cohort|